Shares of Cytokinetics Inc. (CYTK) jumped on Tuesday after the company announced positive results from its pivotal Phase 3 ACACIA-HCM trial. The study, which tested the drug aficamten in patients with symptomatic non-obstructive hypertrophic cardiomyopathy, hit both of its dual primary endpoints.
Non-obstructive hypertrophic cardiomyopathy is a condition where the heart muscle thickens, causing symptoms like shortness of breath, fatigue, and chest pain—but without significant blockage of blood flow. It's a tricky condition to treat, and the results here are a big deal for patients and investors alike.
The trial showed that patients taking aficamten had statistically significant improvements in two key measures compared to those on placebo: the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS), which tracks how patients feel and function, and maximal exercise performance. These weren't just marginal wins; the data were strong enough to drive the stock up 18.38% to $78.19, hitting a new 52-week high.
Beyond the primary endpoints, the drug also showed benefits in several secondary measures. More patients improved their New York Heart Association Functional Class—a standard way to grade heart failure severity—and there were improvements in a composite score of ventilatory efficiency and peak oxygen consumption, as well as reductions in NT-proBNP, a biomarker of heart strain.
So what does this mean for Cytokinetics? The company already has a heart drug on the market—Myqorzo (aficamten) was approved by the FDA earlier this year for obstructive hypertrophic cardiomyopathy. This new data opens the door to treating the non-obstructive form, which could significantly expand the patient population. The European Commission has also approved the drug, so the global opportunity is growing.
On the momentum front, Cytokinetics scores an 83 out of 100 on MarketDash's momentum metric, which is firmly in bullish territory. That means the stock is outperforming the broader market, and with positive trial results in hand, that momentum could attract even more investor interest.
The stock is now trading at a new 52-week high, and the market is clearly betting that aficamten has a bright future. For patients with non-obstructive hypertrophic cardiomyopathy, these results offer hope for a treatment that can actually improve how they feel and function day to day.
